Current Status
Not Enrolled
Price
Closed
Get Started
This course is currently closed
Course
Materials

Chemotherapy-induced nausea and vomiting: an essential update

Thank you for choosing to update your knowledge on the assessment and management of chemotherapy-induced nausea and vomiting (CINV). This activity has been developed specifically for nurses and other members of the healthcare team that manage patients with cancer. It addresses the challenges and consequences of CINV, the goals of CINV management and the therapies used to manage the different phases of CINV. This programme is divided into three modules so that you can complete the activity at your own pace.

This activity will take approximately 2 hours to complete and can be completed at your own pace. You can start the activity today and return at another time to complete it. The work you do is automatically saved and does not need to be repeated if you complete the activity over a number of sessions.

Learning outcomes

  • To determine the patient’s risk for CINV
  • To recognise and overcome barriers to optimal CINV management
  • To implement strategies to help prevent CINV
  • To identify and effectively manage refractory CINV
  • To support the quality use of antiemetics in the management of all phases of CINV

Australian College of Nursing: Endorsed for 2 CPD hours

To earn these points you need to answer at least 80% of the assessment questions correctly.

The educational activities on this site are accredited by healthcare professional organisations including: Australian College of Nursing

ACN Endorsed Course Logo Horizontal

Education Provider:

Scius Healthcare Solutions Pty Ltd
PO Box 84 Northbridge NSW 1560
P +61 2 9958 1481
www.scius.com.au
SCIUS1670 ORBIS‐AU-5358-05 Jan 2020

  1. Janelsins MC, et al. Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother. 2013;14:757-766.
  2. Navari RM. Management of chemotherapy-induced nausea and vomiting : Focus on newer agents and new uses for older agents. Drugs. 2013;73:249-262.
  3. Horn CC. Why is the neurobiology of nausea and vomiting so important? Appetite. 2008;50:430-434.
  4. Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;374:1356-1367.
  5. Vidall C, et al. Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: A cross-sectional multinational survey. Support Care Cancer. 2015;23:3297-3305.
  6. Pirri C, et al. Nausea still the poor relation in antiemetic therapy? The impact on cancer patients' quality of life and psychological adjustment of nausea, vomiting and appetite loss, individually and concurrently as part of a symptom cluster. Support Care Cancer. 2013;21:735-748.
  7. Viale PH, et al. Efficacy and cost: Avoiding undertreatment of chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs. 2012;16:E133-141.
  8. Aapro M, et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): The Pan European Emesis Registry (PEER). Ann Oncol. 2012;23:1986-1992.
  9. eviQ cancer treatments online. Prevention of antineoplastic induced nausea and vomiting. 2019: ID 7 v4.
  10. Frame DG. Best practice management of cinv in oncology patients: I. Physiology and treatment of cinv. Multiple neurotransmitters and receptors and the need for combination therapeutic approaches. J Support Oncol. 2010;8:5-9.
  11. Jordan K, Gralla R, Jahn F, Molassiotis A. International antiemetic guidelines on chemotherapy induced nausea and vomiting (cinv): Content and implementation in daily routine practice. Eur J Pharmacol. 2014;722:197-202
  12. Morrow GR, et al. Nausea and emesis: Evidence for a biobehavioral perspective. Support Care Cancer. 2002;10:96-105.
  13. Martin M. The severity and pattern of emesis following different cytotoxic agents. Oncology. 1996;53 Suppl 1:26-31.
  14. U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE). 2017.
  15. Grunberg SM, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004;100:2261-2268.
  16. Salsman JM, et al. Communicating about chemotherapy-induced nausea and vomiting: A comparison of patient and provider perspectives. J Natl Compr Canc Netw. 2012;10:149-157.
  17. Mertens WC, et al. Improving the care of patients with regard to chemotherapy-induced nausea and emesis: The effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol. 2003;21:1373-1378.
  18. Barak F, et al. Using a simple diary for management of nausea and vomiting during chemotherapy. Clin J Oncol Nurs. 2013;17:479-481.
  19. Thompson N. Optimizing treatment outcomes in patients at risk for chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs. 2012;16:309-313.
  20. Cohen L, et al. Chemotherapy-induced nausea and vomiting: Incidence and impact on patient quality of life at community oncology settings. Support Care Cancer. 2007;15:497-503.
  21. Lindley CM, et al. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res. 1992;1:331-340.
  22. Burke TA, et al. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (cinv) following highly or moderately emetogenic chemotherapy administered in the us outpatient hospital setting. Support Care Cancer. 2011;19:131-140.
  23. Rojas C, Slusher BS. Pharmacological mechanisms of 5-HT(3) and tachykinin NK(1) receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2012;684:1-7.
  24. Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs. 1998;55:173-189.
  25. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology - antiemesis. 2019;Version 1.
  26. Hesketh PJ, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15:103-109.
  27. Hu Z, et al. Personalized estimate of chemotherapy-induced nausea and vomiting: Development and external validation of a nomogram in cancer patients receiving highly/moderately emetogenic chemotherapy. Medicine (Baltimore). 2016;95:e2476.
  28. Gastrointestinal Expert Group. eThearapeutic Guidelines complete. 2019.
  29. eviQ cancer treatments online. Nausea and vomiting during cancer treatment. 2015.
  30. Therapeutic Goods Administration. Australian Register of Therapeutic Goods. 2019.
  31. eviQ cancer treatments online. 2019
  32. Australian Medicines Handbook (online). 2019
  33. Constenla M. 5-HT3 receptor antagonists for prevention of late acute-onset emesis. Ann Pharmacother. 2004;38:1683-1691.
  34. Aapro MS, et al. A phase iii, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 2006;17:1441-1449.
  35. Gralla R, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase iii trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14:1570-1577.
  36. Eisenberg P, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-ht3 receptor antagonist: Results of a phase iii, single-dose trial versus dolasetron. Cancer. 2003;98:2473-2482.
  37. Saito M, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: A double-blind, double-dummy, randomised, comparative phase iii trial. Lancet Oncol. 2009;10:115-124.
  38. Aapro M, et al. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol. 2010;21:1083-1088.
  39. Aloxi® Product Information. February 2019
  40. Aapro M GR, et al. Mascc/esmo antiemetic guideline 2016 with updates in 2019. 2019.
  41. Akynzeo® Product Information. February 2019.
  42. Hesketh PJ, et al. Efficacy and safety of nepa, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: A randomized dose-ranging pivotal study. Ann Oncol. 2014;25:1340-1346.
  43. Spinelli T, et al. Netupitant pet imaging and adme studies in humans. J Clin Pharmacol. 2014;54:97-108.
  44. Aapro M, et al. A randomized phase iii study evaluating the efficacy and safety of nepa, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2014;25:1328-1333.
  45. Gralla RJ, et al. A phase iii study evaluating the safety and efficacy of nepa, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol. 2014;25:1333-1339.
  46. Roila F, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27:v119-v133.
  47. Hesketh PJ, et al. Antiemetics: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2017;35:3240-3261.
  48. Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29:4189-4198.
  49. Dibble SL, et al. Delayed chemotherapy-induced nausea in women treated for breast cancer. Oncol Nurs Forum. 2003;30:E40-47.
  50. Bloechl-Daum B, et al. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24:4472-4478.
  51. Jordan K, et al. Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: Supportive evidence with nepa (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens. Support Care Cancer. 2016;24:4617-4625.
  52. Parapatin (carboplatin) injection USA Product Information. 2010.
  53. Kamen C, et al. Anticipatory nausea and vomiting due to chemotherapy. Eur J Pharmacol. 2014;722:172-179.
  54. Navari RM. Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting. Biomed Res Int. 2015;2015:595894.
  55. eviQ cancer treatments online. Testicular germ cell metastatic bep (bleomycin etoposide cisplatin). 2019;ID: 320 v.3
  56. eviQ cancer treatments online. Breast neoadjuvant AC (doxorubicin and cyclophosphamide) three weekly. 2017; ID 72 v4.